ABSTRACT
In patients with pre-operative anaemia undergoing cardiac surgery, combination treatment with intravenous iron, subcutaneous erythropoietin alpha, vitamin B12 and oral folic acid reduces allogeneic blood product transfusions. It is unclear if certain types of anaemia particularly benefit from this treatment. We performed a post-hoc analysis of anaemic patients from a randomised trial on the 'Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery'. We used linear regression analyses to examine the efficacy of a combination anaemia treatment compared with placebo on the following deficiencies, each representing a part of the combination treatment: ferritin and transferrin saturation; endogenous erythropoietin; holotranscobalamine; and folic acid in erythrocytes. Efficacy was defined as change in reticulocyte count from baseline to the first, third and fifth postoperative days and represented erythropoietic activity in the immediate peri-operative recovery phase. In all 253 anaemic patients, iron deficiency was the most common cause of anaemia. Treatment significantly increased reticulocyte count in all regression analyses on postoperative days 1, 3 and 5 (all p < 0.001). Baseline ferritin and endogenous erythropoietin were negatively associated with change in reticulocyte count on postoperative day 5, with an unstandardised regression coefficient B of -0.08 (95%CI -0.14 to -0.02) and -0.14 (95%CI -0.23 to -0.06), respectively. Quadruple anaemia treatment was effective regardless of the cause of anaemia and its effect manifested early in the peri-operative recovery phase. The more pronounced a deficiency was, the stronger the subsequent boost to erythropoiesis may have been.
Subject(s)
Anemia/drug therapy , Preoperative Care/methods , Administration, Intravenous , Aged , Aged, 80 and over , Anemia, Iron-Deficiency/drug therapy , Blood Transfusion/statistics & numerical data , Cardiac Surgical Procedures/methods , Double-Blind Method , Drug Therapy, Combination , Erythropoietin/administration & dosage , Erythropoietin/therapeutic use , Female , Folic Acid/administration & dosage , Folic Acid/therapeutic use , Hematinics/administration & dosage , Hematinics/therapeutic use , Humans , Iron/administration & dosage , Iron/therapeutic use , Male , Middle Aged , Postoperative Period , Reticulocyte Count , Vitamin B 12/administration & dosage , Vitamin B 12/therapeutic use , Vitamin B Complex/administration & dosage , Vitamin B Complex/therapeutic useSubject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/therapeutic use , Anticoagulants/adverse effects , Dabigatran/adverse effects , Dabigatran/antagonists & inhibitors , Gastrointestinal Hemorrhage/chemically induced , Gastrointestinal Hemorrhage/prevention & control , Aged, 80 and over , Anticoagulants/pharmacokinetics , Blood Coagulation Tests , Dabigatran/pharmacokinetics , Emergency Medical Services , Female , Humans , Kidney Diseases/metabolismABSTRACT
Patients with autoimmune inner ear disease develop rapidly progressive sensorineural hearing loss over a period of several weeks or months, often accompanied by vestibular loss. This disease can occur as a distinct clinical entity or in association with an underlying autoimmune disorder. Treatment comprises immunosuppression by corticosteroids, cytostatic drugs or tumor necrosis factor-α antagonists. We report histopathological and immunohistochemical findings of the inner ear of a patient with a granulomatous inner ear disease suffering from Crohn's disease that was nonresponsive to treatment and who underwent surgery for bilateral cochlear implants.
